by TurquoiseRose
Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
In light of this, a countermeasure that has been shown to be effective in high altitude illness is Acetazolamide.
Acetazolamide has a myriad of effects on different organ systems [20]. It potently reduces hypoxic pulmonary vasoconstriction [21]. Improved minute ventilation and expired vital capacity has been shown in climbers taking Acetazolamide as well [22].
Other therapeutics that have been shown to be effective in the analogous condition of HAPE and that are directed towards decreased pulmonary pressure include Nifedipine and Phosphodiesterase inhibitors (Table (Table2)2) [25,26].
Parameter | HAPE | COVID-19 |
Pao2:FiO2 ratio | Decreased | Decreased |
Hypoxia | Present | Present |
Tachypnea | Increased | Increased |
PaCO2 level | Decreased | Decreased |
Ground Glass Opacities on Chest CT | Present | Present |
Patchy Infiltrates on Chest X-RAY | Present | Present |
Fibrinogen levels/Fibrin formation | Increased | Increased |
Alveolar compromise | Present | Present |
Acute Respiratory Distress Syndrome Development in Severe Disease | Present | Present |
Disclaimer: This is a guest post and it doesn’t represent the views of IWB.
Views: